CRISPR Therapeutics AG

🇺🇸NASDAQ Global Market
Back to all articles
CRISPR Therapeutics AG stock analysis CRSP overview
Somewhat Bearish -25

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

- 🔻 CRISPR Therapeutics AG reported a Q1 loss of $1.28 per share, missing the Zacks consensus estimate of -$1.14.

- 📉 The earnings surprise for the quarter was -12.39%, following a previous quarter's surprise of -19.13%.

- 💸 Revenue reached $1.46 million for the quarter ended March 2026, falling significantly short of the consensus by 82.62%.

- 📊 The company has failed to beat consensus revenue estimates in any of the last four consecutive quarters.

- 📈 Despite posting a loss, adjusted Q1 earnings show an improvement year-over-year compared to a loss of $1.58 per share last year.

- 🔜 Management commentary on the upcoming earnings call will likely be the primary driver for future stock price movement.

- ⚠️ Shares have underperformed the market with a 1.5% decline this year, contrasting against the S&P 500's 5.6% gain.

- 📉 The current Zacks Rank is #3 (Hold), suggesting shares are expected to perform in line with the broader market near-term.

- 📅 Analysts expect losses of -$1.19 per share for the coming quarter and -$4.93 per share for the full fiscal year.

- 🏥 The parent "Medical - Biomedical and Genetics" industry is ranked in the bottom 44% of all Zacks-ranked industries.

- 🔭 Upcoming peer Immunome, Inc. (IMNM) is expected to report a quarterly loss of $0.60 with revenues down 31.7%.

- 📈 Research indicates that top-ranked industries historically outperform bottom-ranked ones by a factor of more than two to one.

- 📝 Investors are advised to monitor earnings estimate revisions as they correlate strongly with short-term stock price trends.

- 🆓 The article concludes with promotional links for free stock analysis reports and Zacks investment research recommendations.

Bullish Signals
  • Year-over-year revenue grew from $0.87 million to $1.46 million, demonstrating top-line growth despite missing estimates.
  • Over the last four quarters, the company has surpassed consensus EPS estimates on two occasions, indicating periods of positive earnings performance.
  • The year-over-year loss narrowed from $1.58 per share to $1.28 per share, reflecting an improvement in quarterly profitability compared to the same period last year.
Risk Factors
  • CRISPR Therapeutics reported a quarterly loss of $1.28 per share, missing the consensus estimate of $1.14 by 12.39%.
  • The company failed to beat revenue estimates for four consecutive quarters, with Q1 revenues of $1.46 million missing the consensus by 82.62%.
  • Shares have underperformed the market significantly, losing approximately 1.5% year-to-date compared to the S&P 500's gain of 5.6%.
  • The stock carries a Zacks Rank #3 (Hold) based on mixed estimate revisions and expectations to perform in line with the market rather than outperforming.
  • CRISPR Therapeutics trades in the 'Medical - Biomedical and Genetics' industry, which is currently ranked in the bottom 44% of all Zacks industries.
  • Future stock performance relies heavily on management's commentary, as there are no clear positive drivers to offset the recent earnings miss.
Full Analysis
CRISPR Therapeutics AG (CRSP) reported first-quarter earnings that missed both analyst estimates for loss and revenue. The company posted an adjusted loss of $1.28 per share, compared to the consensus expectation of a $1.14 loss and its own prior period's loss of $1.58. Revenue came in at $1.46 million, significantly below the estimated $1.79 million (an 82.62% miss), marking the fourth consecutive quarter where the company failed to beat revenue expectations. This earnings surprise represents a -12.39% miss versus consensus, following a similar miss of -19.13% in the previous quarter's adjusted loss. Although CRSP had outperformed estimates twice in the last four quarters, the consistent failure to meet revenue targets is a notable trend. Since the start of the year, CRSP shares have declined by approximately 1.5%, underperforming the S&P 500 which rose 5.6%. Looking ahead, analysts expect continued challenges for the biotech sector, with the Zacks Medical - Biomedical and Genetics industry currently ranked in the bottom 44% of all tracked industries. For the upcoming quarter, the consensus EPS estimate is -$1.19 on projected revenues of $8.67 million, while the full-year fiscal estimate stands at a loss of -$4.93 on $35.78 million in revenue. Consequently, Zacks Investment Research maintains a Zacks Rank of #3 (Hold) for CRSP, suggesting shares are expected to perform roughly in line with the market pending further guidance from management regarding future earnings outlooks and industry tailwinds.